Brand Name: Esbriet®
Pirfenidone is a drug developed by InterMune Inc. for the treatment of idiopathic pulmonary fibrosis (IPF). In 2011 it was approved for use in Europe for IPF under the trade name Esbriet.The proposed trade name in the US is also Esbriet.
* Note: All prices in Bitcoin (BTC). The Bitcoin exchange rate is calculated using an average price from several leading exchange providers. Local currency conversions are provided for your convenience.
† The pharmacy dispenses the product displayed. In the case of a product shortage, the pharmacy may substitute with an alternative generic.
Other Known Brand Names for Esbriet
- Pirfenex (Cipla Limited)
ESBRIET (pirfenidone) is indicated for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in adults
Treatment with ESBRIET should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of IPF. ESBRIET should be taken with food. ESBRIET should not be taken concomitantly with fluvoxamine and ciprofloxacin.
Disclaimer: Information and data on Pirfenidone (generic Esbriet®) found on this website is for informational purposes only. This information does not constitute legal advice and it is recommended to first check all information with your medical practitioner.